AI Agents That Accelerate Drug Discovery

AI agents analyze molecular structures, predict binding affinities, and screen thousands of drug candidates computationally — work that would take human researchers months. This narrows the funnel from millions of molecules to a shortlist of high-probability candidates before any wet-lab work begins, reducing preclinical timelines by 30-50%.

AI models analyze historical trial data, patient biomarkers, and protocol parameters to predict enrollment rates, adverse event probabilities, and efficacy signals. This enables adaptive trial designs that reduce failure risk and accelerate timelines by optimizing patient selection and dosing strategies.

Our implementations follow FDA 21 CFR Part 11 for electronic records, ICH E6(R2) for GCP compliance, and GAMP 5 for computerized system validation. Every AI decision includes complete audit trails, model versioning, and validation documentation ready for regulatory review.

AI-powered molecular modeling uses deep learning to predict protein structures, simulate drug-target interactions, and optimize ADMET properties (Absorption, Distribution, Metabolism, Excretion, Toxicity). This replaces months of computational chemistry with hours of AI-driven analysis.

Yes. AI agents analyze EHR data, genomic profiles, and inclusion/exclusion criteria to identify eligible patients 10x faster than manual screening. They can also predict enrollment velocity and optimize site selection — the two biggest bottlenecks in clinical trial execution.

Retrieval-Augmented Generation connects AI agents to your proprietary data — research papers, trial protocols, safety databases, competitor intelligence — without retraining models. Researchers get answers grounded in your organization's knowledge, not generic internet data.

All AI models run within your security perimeter. Patient data never leaves your environment. We implement differential privacy, data anonymization, and encryption at rest and in transit. Full compliance with HIPAA, GDPR, and 21 CFR Part 11.

AI agents monitor real-world evidence (RWE), patient reports, and clinical signals in real-time to detect safety signals earlier than traditional pharmacovigilance methods. This can reduce detection lag from months to days, potentially preventing serious adverse events.

Typical outcomes: 30-50% reduction in preclinical timelines, 40% faster clinical trial enrollment, 25-35% reduction in protocol deviations, and significant improvement in candidate success rates. For a single drug program, this can translate to $100M+ in accelerated revenue.

We connect AI agents to LIMS (Laboratory Information Management Systems), ELN (Electronic Lab Notebooks), and CTMS (Clinical Trial Management Systems) via secure APIs and Model Context Protocol (MCP). No disruption to existing workflows — the AI layer augments what you already have.